In contrast to cardiorenal syndrome ... should the enhancement of cardiovascular death initiated by kidney disease be termed 'renocardiac syndrome'? As the kidney is the primary regulator of ...

We call the interaction between chronic renal failure, CHF and anemia the cardiorenal anemia syndrome. Each of these three elements causes or exacerbates the others, and their correction can ...

Cardiorenal syndrome (CRS) commonly occurs during treatment of acute decompensated heart failure (ADHF) and is associated with poor clinical outcome. The pathophysiology of CRS entails a complex ...

This is an important, but poorly understood, cause of morbidity and mortality in human and veterinary patients. The Comparative Cardiorenal Research Group is a unique collaboration between medical and ...

Empagliflozin continues to offer cardiorenal benefits for up to 12 months after discontinuation among patients with chronic kidney disease at risk for progression, according to a study published ...

Generated 3Q 2024 net FUROSCIX® revenue of $10.0 million, up 164% from Q3 2023 Received approval of label expansion to include New York Heart ...

Scpharmaceuticals ( (SCPH) ) has released its Q3 earnings. Here is a breakdown of the information Scpharmaceuticals presented to its investors.